Ibrutinib combination therapy in CLL: overview of the data so far - 101793

Spotlight
Video

Ibrutinib combination therapy in CLL: overview of the data so far

VJHemOnc has 915 videos Subscribe Here

Loading........
Description: Ibrutinib combination therapy in an exciting therapeutic area with great potential. Many recent and ongoing studies are seeking to identify the optimal ibrutinib combinations for the treatment of chronic lymphocytic leukemia (CLL). Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, George Follows, BMBCh, PhD, FRCP, FRCPath, of Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, highlights data that was presented at the meeting which evaluated ibrutinib combination therapy for CLL, including that with venetoclax and anti-CD20 antibodies.
Shared By : VJHemOnc
Posted on : 02/09/18
Added : 10 days ago



Recommended

Nothing found.

More From VJHemOnc

Nothing found.